Exploring 2026 Ucsf Stanford Summit Debate 2 Should Biosimilars Be Approved
Exploring 2026 Ucsf Stanford Summit Debate 2 Should Biosimilars Be Approved reveals several interesting facts.
- Speaker: Russ Altman, MD PhD, Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and ...
- Speaker: Kathy Giacomini, PhD BSPharm, Dean, School of Pharmacy,
- Speakers: Kathy Giacomini, PhD, BSPharm – Dean,
- Panel 4: Innovation at a Crossroads: Science, Strategy, Policy, and Global Forces Shaping Biopharma's Future Moderator: Andy ...
- Panel 1: What Are the Major Barriers to Drug Development and
In-Depth Information on 2026 Ucsf Stanford Summit Debate 2 Should Biosimilars Be Approved
Moderators: Robert Califf, MD, former FDA Commissioner Joseph Wu, MD, PhD, Professor and Director, Speakers: James Fraser, PhD, Professor and Chair, Department of Bioengineering and Therapeutic Sciences, Moderators: Kuldev Singh, MD, MPH – Professor of Ophthalmology, Panel
CBAI Symposium Keynote Speaker John Marioni, senior vice president and global head of computational sciences at Genentech.
Stay tuned for more updates related to 2026 Ucsf Stanford Summit Debate 2 Should Biosimilars Be Approved.